Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

Sang Joon Shin, Jae Heon Jeong, Young Suk Park, Kyung Hee Lee, Byoung Yong Shim, Tae Won Kim, Do Youn Oh, Myung Ah Lee, Yong Tai Kim, Yeul Hong Kim, Dae Young Zang, Jae Kyung Roh, Joong Bae Ahn

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A phase II study was conducted to evaluate S-1 monotherapy in previously untreated elderly or frail metastatic colorectal cancer patients. A total of 48 elderly (70-85 years old) and frail [Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 and 65-69 years old] patients were eligible for first-line S-1 of 35 mg/m 2 given twice daily for 2 weeks followed by 1 week of rest. The overall response rate (ORR) for all patients was 19%. Similarly, the ORR for frail and elderly patients was 22% and 18%, respectively. Median progression-free survival (PFS) and overall survival (OS) for all patients were 3.9 months (95% CI, 3.0-4.8) and 11.3 months (95% CI, 7.4-15.2), respectively. For frail patients, PFS was 1.4 (95% CI, 0.8-2.0) vs. 4.3 months (95% CI, 3.0-5.4) for the elderly (P=0.016). OS was significantly longer for elderly patients than for frail patients (13.1 months, 95% CI, 9.5-16.7) vs. (4.1 months, 95% CI, 3.2-5.0; P=0.01). Toxicity was mild to moderate, as only 29% of patients experienced grade 3 toxicity. Grade 4 toxicity and febrile neutropenia did not occur; however, two frail patients died from grade 5 treatment-related infections. Generally, S-1 monotherapy was well-tolerated and efficacious in the elderly patient group, but not in the frail patient group. Considering performance status and co-morbidities in patients >70 years old, S-1 monotherapy may be a first-line therapeutic option for elderly mCRC patients.

Original languageEnglish
Pages (from-to)1073-1080
Number of pages8
JournalInvestigational New Drugs
Volume29
Issue number5
DOIs
Publication statusPublished - 2011 Oct 1

Fingerprint

Frail Elderly
Colorectal Neoplasms
Disease-Free Survival
Febrile Neutropenia
Survival

Keywords

  • Colorectal cancer
  • Elderly
  • Frail
  • S-1

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Oncology

Cite this

Shin, S. J., Jeong, J. H., Park, Y. S., Lee, K. H., Shim, B. Y., Kim, T. W., ... Ahn, J. B. (2011). Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. Investigational New Drugs, 29(5), 1073-1080. https://doi.org/10.1007/s10637-010-9418-2

Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. / Shin, Sang Joon; Jeong, Jae Heon; Park, Young Suk; Lee, Kyung Hee; Shim, Byoung Yong; Kim, Tae Won; Oh, Do Youn; Lee, Myung Ah; Kim, Yong Tai; Kim, Yeul Hong; Zang, Dae Young; Roh, Jae Kyung; Ahn, Joong Bae.

In: Investigational New Drugs, Vol. 29, No. 5, 01.10.2011, p. 1073-1080.

Research output: Contribution to journalArticle

Shin, SJ, Jeong, JH, Park, YS, Lee, KH, Shim, BY, Kim, TW, Oh, DY, Lee, MA, Kim, YT, Kim, YH, Zang, DY, Roh, JK & Ahn, JB 2011, 'Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer', Investigational New Drugs, vol. 29, no. 5, pp. 1073-1080. https://doi.org/10.1007/s10637-010-9418-2
Shin, Sang Joon ; Jeong, Jae Heon ; Park, Young Suk ; Lee, Kyung Hee ; Shim, Byoung Yong ; Kim, Tae Won ; Oh, Do Youn ; Lee, Myung Ah ; Kim, Yong Tai ; Kim, Yeul Hong ; Zang, Dae Young ; Roh, Jae Kyung ; Ahn, Joong Bae. / Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer. In: Investigational New Drugs. 2011 ; Vol. 29, No. 5. pp. 1073-1080.
@article{72c3cb5b016040a5b9d2e8b95c02307d,
title = "Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer",
abstract = "A phase II study was conducted to evaluate S-1 monotherapy in previously untreated elderly or frail metastatic colorectal cancer patients. A total of 48 elderly (70-85 years old) and frail [Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 and 65-69 years old] patients were eligible for first-line S-1 of 35 mg/m 2 given twice daily for 2 weeks followed by 1 week of rest. The overall response rate (ORR) for all patients was 19{\%}. Similarly, the ORR for frail and elderly patients was 22{\%} and 18{\%}, respectively. Median progression-free survival (PFS) and overall survival (OS) for all patients were 3.9 months (95{\%} CI, 3.0-4.8) and 11.3 months (95{\%} CI, 7.4-15.2), respectively. For frail patients, PFS was 1.4 (95{\%} CI, 0.8-2.0) vs. 4.3 months (95{\%} CI, 3.0-5.4) for the elderly (P=0.016). OS was significantly longer for elderly patients than for frail patients (13.1 months, 95{\%} CI, 9.5-16.7) vs. (4.1 months, 95{\%} CI, 3.2-5.0; P=0.01). Toxicity was mild to moderate, as only 29{\%} of patients experienced grade 3 toxicity. Grade 4 toxicity and febrile neutropenia did not occur; however, two frail patients died from grade 5 treatment-related infections. Generally, S-1 monotherapy was well-tolerated and efficacious in the elderly patient group, but not in the frail patient group. Considering performance status and co-morbidities in patients >70 years old, S-1 monotherapy may be a first-line therapeutic option for elderly mCRC patients.",
keywords = "Colorectal cancer, Elderly, Frail, S-1",
author = "Shin, {Sang Joon} and Jeong, {Jae Heon} and Park, {Young Suk} and Lee, {Kyung Hee} and Shim, {Byoung Yong} and Kim, {Tae Won} and Oh, {Do Youn} and Lee, {Myung Ah} and Kim, {Yong Tai} and Kim, {Yeul Hong} and Zang, {Dae Young} and Roh, {Jae Kyung} and Ahn, {Joong Bae}",
year = "2011",
month = "10",
day = "1",
doi = "10.1007/s10637-010-9418-2",
language = "English",
volume = "29",
pages = "1073--1080",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "5",

}

TY - JOUR

T1 - Phase II trial of S-1 monotherapy in elderly or frail patients with metastatic colorectal cancer

AU - Shin, Sang Joon

AU - Jeong, Jae Heon

AU - Park, Young Suk

AU - Lee, Kyung Hee

AU - Shim, Byoung Yong

AU - Kim, Tae Won

AU - Oh, Do Youn

AU - Lee, Myung Ah

AU - Kim, Yong Tai

AU - Kim, Yeul Hong

AU - Zang, Dae Young

AU - Roh, Jae Kyung

AU - Ahn, Joong Bae

PY - 2011/10/1

Y1 - 2011/10/1

N2 - A phase II study was conducted to evaluate S-1 monotherapy in previously untreated elderly or frail metastatic colorectal cancer patients. A total of 48 elderly (70-85 years old) and frail [Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 and 65-69 years old] patients were eligible for first-line S-1 of 35 mg/m 2 given twice daily for 2 weeks followed by 1 week of rest. The overall response rate (ORR) for all patients was 19%. Similarly, the ORR for frail and elderly patients was 22% and 18%, respectively. Median progression-free survival (PFS) and overall survival (OS) for all patients were 3.9 months (95% CI, 3.0-4.8) and 11.3 months (95% CI, 7.4-15.2), respectively. For frail patients, PFS was 1.4 (95% CI, 0.8-2.0) vs. 4.3 months (95% CI, 3.0-5.4) for the elderly (P=0.016). OS was significantly longer for elderly patients than for frail patients (13.1 months, 95% CI, 9.5-16.7) vs. (4.1 months, 95% CI, 3.2-5.0; P=0.01). Toxicity was mild to moderate, as only 29% of patients experienced grade 3 toxicity. Grade 4 toxicity and febrile neutropenia did not occur; however, two frail patients died from grade 5 treatment-related infections. Generally, S-1 monotherapy was well-tolerated and efficacious in the elderly patient group, but not in the frail patient group. Considering performance status and co-morbidities in patients >70 years old, S-1 monotherapy may be a first-line therapeutic option for elderly mCRC patients.

AB - A phase II study was conducted to evaluate S-1 monotherapy in previously untreated elderly or frail metastatic colorectal cancer patients. A total of 48 elderly (70-85 years old) and frail [Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 and 65-69 years old] patients were eligible for first-line S-1 of 35 mg/m 2 given twice daily for 2 weeks followed by 1 week of rest. The overall response rate (ORR) for all patients was 19%. Similarly, the ORR for frail and elderly patients was 22% and 18%, respectively. Median progression-free survival (PFS) and overall survival (OS) for all patients were 3.9 months (95% CI, 3.0-4.8) and 11.3 months (95% CI, 7.4-15.2), respectively. For frail patients, PFS was 1.4 (95% CI, 0.8-2.0) vs. 4.3 months (95% CI, 3.0-5.4) for the elderly (P=0.016). OS was significantly longer for elderly patients than for frail patients (13.1 months, 95% CI, 9.5-16.7) vs. (4.1 months, 95% CI, 3.2-5.0; P=0.01). Toxicity was mild to moderate, as only 29% of patients experienced grade 3 toxicity. Grade 4 toxicity and febrile neutropenia did not occur; however, two frail patients died from grade 5 treatment-related infections. Generally, S-1 monotherapy was well-tolerated and efficacious in the elderly patient group, but not in the frail patient group. Considering performance status and co-morbidities in patients >70 years old, S-1 monotherapy may be a first-line therapeutic option for elderly mCRC patients.

KW - Colorectal cancer

KW - Elderly

KW - Frail

KW - S-1

UR - http://www.scopus.com/inward/record.url?scp=84856076344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856076344&partnerID=8YFLogxK

U2 - 10.1007/s10637-010-9418-2

DO - 10.1007/s10637-010-9418-2

M3 - Article

VL - 29

SP - 1073

EP - 1080

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 5

ER -